



MEDICAL DEVICES



PHARMACEUTICALS



CHEMICALS



FOOD & BEVERAGE



ELECTRONICS

This report is being updated. Subscribers will receive complimentary copies of the previous edition while the new report is in preparation.

# Top 10

## World's Leading LIFE SCIENCE INTERMEDIATES Companies

A THOUGHT-PROVOKING REPORT ON PERFORMANCE, CAPABILITIES, GOALS AND STRATEGIES OF THE MAJOR COMPETITORS IN THE WORLDWIDE LIFE SCIENCE INTERMEDIATES MARKET

- BASF
- Bayer
- Cambrex
- Clariant
- DowPharma
- DSM
- Evonik
- Lonza
- Novasep
- Rhodia

Available by Company and Section!

Contains nearly 560 pages and 80 tables

Includes a 55-page Worldwide Market Overview

**Visit [www.vpgcorp.com](http://www.vpgcorp.com) to review this and over 5,000 reports**



VENTURE PLANNING GROUP

[WWW.VPGCORP.COM](http://WWW.VPGCORP.COM)

INFORMATION • INTELLIGENCE • ANALYSIS • INSIGHT

## Worldwide Market Overview

A concise market analysis, including:

- Major U.S. and international trends with potentially significant impact on the life science intermediates industry during the next five years, including industry consolidation, market globalization, environmental regulations, etc.
- Analysis of major market segments.
- Review of key geographic regions, including North America, Europe, Asia, Latin America and others.
- Five-year worldwide market forecasts for:
  - Major market segments.
  - Key geographic regions.

## Company Strategic Assessments

For each of the **Top 10** companies, the report provides an approximately **55-page** strategic analysis, including the following information:

### SECTION I. EXECUTIVE SUMMARY

- A 3-5 page synopsis of main sections.

### SECTION II. BUSINESS ORGANIZATION

- History of the life science intermediates business evolution, important to the understanding of the corporate culture, management mentality and strategies.
- Recent acquisitions, divestitures and significant organizational changes.
- Current organizational structure.

### SECTION III. SENIOR MANAGEMENT

- Background of key executives.

### SECTION IV. FACILITIES AND EMPLOYEES

- Major administrative, manufacturing and R&D facilities in the U.S. and abroad.
- New plants under construction.
- U.S. and international work force size and distribution.

### SECTION V. TECHNOLOGICAL KNOW-HOW

- Internally developed and acquired technologies, and related capabilities.
- Proprietary technologies and patent litigations.

### SECTION VI. PRODUCT PORTFOLIO

- Extensive review of major product lines.
- New product introductions and line extensions.

### SECTION VII. MARKETING TACTICS

- Major promotional strategies.
- Distribution approaches.
- Product service and support.

### SECTION VIII. FINANCIAL ANALYSIS

- Sales and operating profit by division, product line, geographic region and country.
- Five-year sales and profit performance.

### SECTION IX. R&D EXPENDITURES AND MAJOR PROGRAMS

- Estimated R&D budget.
- Research facilities and staff.
- New technologies, products and applications in development.

### SECTION X. COLLABORATIVE ARRANGEMENTS

- Major joint venture, distribution, OEM and licensing partners, both industrial and academic.
- Terms of collaborative agreements and specific products involved.

### SECTION XI. STRATEGIC DIRECTION

- Specific business, new product development and marketing strategies.
- Strengths and weaknesses.
- Anticipated acquisitions, joint ventures and divestitures.

## Comparative Analysis

In this section of the report, the **Top 10** companies are ranked according to the following criteria:

- Estimated sales in Europe, North America, Asia,

and other geographic regions.

- Operating profit.
- R&D expenditures.

# LIST OF TABLES

|   |  |  |
|---|--|--|
| <b>TABLE BF-1:</b> BASF SALES AND OPERATING PROFIT GROWTH                     | <b>TABLE CL-5:</b> CLARIANT SALES BY GEOGRAPHIC REGION                         | <b>TABLE DS-1:</b> GROUPE NOVASEP PROFORMA SALES BY CUSTOMER GROUP                                       |
| <b>TABLE BF-2:</b> BASF SALES BY BUSINESS SEGMENT                             | <b>TABLE DE-1:</b> EVONIK SALES AND OPERATING PROFIT GROWTH                    | <b>TABLE LO-1:</b> LONZA SALES AND OPERATING PROFIT GROWTH   |
| <b>TABLE BF-3:</b> BASF SALES GROWTH BY BUSINESS SEGMENT                      | <b>TABLE DE-2:</b> EVONIK SALES BY DIVISION                                    | <b>TABLE LO-2:</b> LONZA SALES BY DIVISION   |
| <b>TABLE BF-4:</b> BASF OPERATING PROFIT BY BUSINESS SEGMENT                  | <b>TABLE DE-3:</b> EVONIK SALES GROWTH BY DIVISION                             | <b>TABLE LO-3:</b> LONZA SALES GROWTH BY DIVISION  |
| <b>TABLE BF-5:</b> BASF PLASTICS SALES BY DIVISION                            | <b>TABLE DE-4:</b> EVONIK FINE AND INDUSTRIAL CHEMICAL SALES BY BUSINESS UNIT  | <b>TABLE LO-4:</b> LONZA OPERATING PROFIT BY DIVISION  |
| <b>TABLE BF-6:</b> BASF PERFORMANCE PRODUCTS SALES BY DIVISION                | <b>TABLE DE-5:</b> EVONIK COATINGS AND ADVANCED FILLERS SALES BY BUSINESS UNIT | <b>TABLE LO-5:</b> LONZA OPERATING PROFIT GROWTH BY DIVISION   |
| <b>TABLE BF-7:</b> BASF CHEMICAL SALES BY DIVISION                            | <b>TABLE DE-6:</b> EVONIK PERFORMANCE MATERIALS SALES BY BUSINESS UNIT         | <b>TABLE LO-6:</b> LONZA EXCLUSIVE SYNTHESIS & BIOPHARMACEUTICAL DIVISION SALES BY MOLECULAR SIZE        |
| <b>TABLE BF-8:</b> BASF AGRICULTURAL PRODUCTS AND NUTRITION SALES BY DIVISION | <b>TABLE DE-7:</b> EVONIK CONSTRUCTION CHEMICALS SALES BY BUSINESS UNIT        | <b>TABLE LO-7:</b> LONZA EXCLUSIVE SYNTHESIS & BIOPHARMACEUTICAL DIVISION SALES GROWTH BY MOLECULAR SIZE |
| <b>TABLE BF-9:</b> BASF SALES BY GEOGRAPHIC REGION                            | <b>TABLE DE-8:</b> EVONIK SPECIALTY POLYMERS SALES BY BUSINESS UNIT            | <b>TABLE LO-8:</b> LONZA SALES BY GEOGRAPHIC REGION  |
| <b>TABLE BR-1:</b> BAYER SALES BY BUSINESS SEGMENT                            | <b>TABLE DE-9:</b> EVONIK SALES BY GEOGRAPHIC REGION AND COUNTRY               | <b>TABLE LO-9:</b> LONZA SALES GROWTH BY GEOGRAPHIC REGION   |
| <b>TABLE BR-2:</b> BAYER SALES GROWTH BY BUSINESS SEGMENT                     | <b>TABLE DO-1:</b> DOW CHEMICAL SALES AND OPERATING PROFIT GROWTH              | <b>TABLE LO-10:</b> LONZA EXCLUSIVE SYNTHESIS & PHARMACEUTICALS SALES BY GEOGRAPHIC REGION               |
| <b>TABLE BR-3:</b> BAYER SALES BY GEOGRAPHIC REGION                           | <b>TABLE DO-2:</b> DOW CHEMICAL SALES BY OPERATING SEGMENT                     | <b>TABLE LO-11:</b> LONZA EXCLUSIVE SYNTHESIS & PHARMACEUTICALS SALES GROWTH BY GEOGRAPHIC REGION        |
| <b>TABLE BR-4:</b> BAYER SALES GROWTH BY GEOGRAPHIC REGION                    | <b>TABLE DO-3:</b> DOW CHEMICAL SALES GROWTH BY OPERATING SEGMENT              | <b>TABLE LO-12:</b> LONZA ORGANIC FINE & PERFORMANCE CHEMICALS SALES BY GEOGRAPHIC REGION                |
| <b>TABLE BR-5:</b> LANXESS SALES AND OPERATING PROFIT GROWTH                  | <b>TABLE DO-4:</b> DOW CHEMICAL SALES BY GEOGRAPHIC REGION                     | <b>TABLE LO-13:</b> LONZA ORGANIC FINE & PERFORMANCE CHEMICALS SALES GROWTH BY GEOGRAPHIC REGION         |
| <b>TABLE BR-6:</b> LANXESS SALES BY PRODUCT LINE                              | <b>TABLE DO-5:</b> DOW CHEMICAL SALES GROWTH BY GEOGRAPHIC REGION              | <b>TABLE LO-14:</b> LONZA POLYMER INTERMEDIATES SALES BY GEOGRAPHIC REGION                               |
| <b>TABLE BR-7:</b> LANXESS SALES GROWTH BY PRODUCT LINE                       | <b>TABLE DM-1:</b> DSM SALES AND OPERATING PROFIT GROWTH                       | <b>TABLE LO-15:</b> LONZA POLYMER INTERMEDIATES SALES GROWTH BY GEOGRAPHIC REGION                        |
| <b>TABLE CX-1:</b> CAMBREX SALES AND OPERATING PROFIT GROWTH                  | <b>TABLE DM-2:</b> DSM SALES BY DIVISION                                       | <b>TABLE RH-1:</b> RHODIA SALES AND OPERATING PROFIT GROWTH  |
| <b>TABLE CX-2:</b> CAMBREX SALES BY BUSINESS SEGMENT                          | <b>TABLE DM-3:</b> DSM SALES GROWTH BY DIVISION                                | <b>TABLE RH-2:</b> RHODIA SALES BY ENTERPRISE  |
| <b>TABLE CX-3:</b> CAMBREX SALES GROWTH BY BUSINESS SEGMENT                   | <b>TABLE DM-4:</b> DSM OPERATING PROFIT BY DIVISION                            | <b>TABLE RH-3:</b> RHODIA SALES GROWTH BY ENTERPRISE   |
| <b>TABLE CX-4:</b> CAMBREX OPERATING PROFIT AND MARGINS BY BUSINESS SEGMENT   | <b>TABLE DM-5:</b> DSM OPERATING PROFIT GROWTH BY DIVISION                     | <b>TABLE RH-4:</b> RHODIA OPERATING PROFIT AND MARGINS BY ENTERPRISE                                     |
| <b>TABLE CX-5:</b> CAMBREX OPERATING PROFIT GROWTH BY BUSINESS SEGMENT        | <b>TABLE DM-6:</b> DSM LIFE SCIENCE PRODUCTS SALES BY BUSINESS GROUP           | <b>TABLE RH-5:</b> RHODIA OPERATING PROFIT GROWTH BY ENTERPRISE  |
| <b>TABLE CX-6:</b> CAMBREX SALES BY PRODUCT GROUP                             | <b>TABLE DM-7:</b> DSM LIFE SCIENCE PRODUCTS SALES GROWTH BY BUSINESS GROUP    | <b>TABLE RH-6:</b> RHODIA SALES BY GEOGRAPHIC REGION AND COUNTRY   |
| <b>TABLE CX-7:</b> CAMBREX SALES GROWTH BY PRODUCT GROUP                      | <b>TABLE DM-8:</b> DSM PERFORMANCE MATERIALS SALES BY BUSINESS GROUP           | <b>TABLE RH-7:</b> RHODIA SALES GROWTH BY GEOGRAPHIC REGION AND COUNTRY                                  |
| <b>TABLE CX-8:</b> CAMBREX SALES BY GEOGRAPHIC REGION                         | <b>TABLE DM-9:</b> DSM PERFORMANCE MATERIALS SALES GROWTH BY BUSINESS GROUP    |  |
| <b>TABLE CX-9:</b> CAMBREX SALES GROWTH BY GEOGRAPHIC REGION                  | <b>TABLE DM-10:</b> DSM INDUSTRIAL CHEMICALS SALES BY BUSINESS GROUP           |  |
| <b>TABLE CL-1:</b> CLARIANT SALES BY DIVISION                                 | <b>TABLE DM-11:</b> DSM INDUSTRIAL CHEMICALS SALES GROWTH BY BUSINESS GROUP    |  |
| <b>TABLE CL-2:</b> CLARIANT SALES GROWTH BY DIVISION                          |  |  |
| <b>TABLE CL-3:</b> CLARIANT PROFIT BY DIVISION                                |  |  |
| <b>TABLE CL-4:</b> CLARIANT PROFIT GROWTH BY DIVISION                         |  |  |

# ABOUT THIS REPORT

## Rationale

A strategic assessment of the competitive environment is becoming widely recognized as one of the highest priority management responsibilities, the task crucial to business survival, growth and profitability. Timely and factual competitive intelligence is vital to the success of all business functions, particularly Planning, Marketing, R&D, and Manufacturing.

In a highly dynamic and fragmented life science intermediates market, besieged by intense competition and rapid pace of technological innovations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important... and can spell the difference between success and failure.

## Objectives

**"THE TOP 10 WORLD'S LEADING LIFE SCIENCE INTERMEDIATES COMPANIES"** is a unique multi-client study prepared by VENTURE PLANNING GROUP in order to provide industry executives with strategically significant competitor information, analysis and insight crucial to the development and implementation of effective business, marketing and R&D programs. The study's major objectives include:

- To establish a comprehensive, factual and cost-effective

information base on performance, capabilities, goals and strategies of the world's leading life science intermediates companies.

- To help current suppliers realistically assess their financial, technological and marketing capabilities vis-a-vis leading competitors.
- To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates.
- To complement organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.

## Methodology

The **Top 10** report is based on a combination of primary and secondary information sources, including experts from trade associations, and others knowledgeable of the companies' current operations and future strategic directions. The information generated at industry shows, marketing conferences and at industry shows, marketing conferences and scientific symposia was also included data retrieved from Venture Planning Group's proprietary information base, developed during the firm's continuous

monitoring of the industry, as well as over 100 syndicated multiclient studies and numerous proprietary single-client assignments. This database contains information on major chemical companies, technologies, products and executives worldwide.

Moreover, a comprehensive review of the **Top 10** companies' product and financial literature, business and technical periodicals, pertinent industry analyst reports was conducted.

## Special Features

- **560 pages** of vital market intelligence.
- **80 tables** containing estimates of the **Top 10** companies' sales and operating profit by division, geographic region and product line.
- **Worldwide Market Overview**, including sales forecasts for major

geographic regions and market segments.

- **Comparative Analysis** ranking the **Top 10** companies according to their sales, profit and R&D expenditures.

# ORDER FORM

TO: VENTURE PLANNING GROUP

350 Fifth Avenue • Suite 3304 • New York • NY • 10118 tel. 212.564.2838 fax. 212.564.8133 info@vpgcorp.com

I am interested in your new study:

## “The Top 10 World’s Leading Life Science Intermediates Companies”

I am interested in a complete 10-company report:

|                                      | Before<br>Feb. 20, 2009 | After<br>Feb. 20, 2009 |
|--------------------------------------|-------------------------|------------------------|
| <input type="checkbox"/> PDF .....   | \$9,600 .....           | \$11,400               |
| <input type="checkbox"/> Print ..... | 7,900 .....             | 9,500                  |
| <input type="checkbox"/> Both .....  | 12,300 .....            | 14,600                 |

I am interested in the following individual company assessments:

- BASF     Clariant     DSM     Groupe Novasep     Lonza  
 Cambrex     Dowpharma     Evonik     Lanxess     Rhodia

Cost per company:

|                                      | Before<br>Feb. 20, 2009 | After<br>Feb. 20, 2009 |
|--------------------------------------|-------------------------|------------------------|
| <input type="checkbox"/> PDF .....   | \$1,250 .....           | \$1,500                |
| <input type="checkbox"/> Print ..... | 1,050 .....             | 1,250                  |
| <input type="checkbox"/> Both .....  | 1,600 .....             | 1,900                  |

name: \_\_\_\_\_ title: \_\_\_\_\_

company: \_\_\_\_\_

address: \_\_\_\_\_

city: \_\_\_\_\_ state: \_\_\_\_\_

zip: \_\_\_\_\_ country: \_\_\_\_\_

telephone: \_\_\_\_\_ fax: \_\_\_\_\_

email: \_\_\_\_\_

### Payment Options

- Check payable to Venture Planning Group     Please send me an invoice     Please charge my credit card

card type:  Visa     MasterCard     AMEX     Other

cardholder's name: \_\_\_\_\_

card number: \_\_\_\_\_

expiration date: \_\_\_\_\_

signature: \_\_\_\_\_



WWW.VPGCORP.COM